Develops innovative therapeutic assets focused on oncology. Operates through its subsidiary, SkinJect Inc., specializing in non-invasive cancer treatments. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
A loss of $25.4M against $0 in annual sales.
The stock sits at $0.30. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At last year’s rate of cash burn, the cash lasts less than a year. After that, the company needs to find new money.
No MoonshotScore has been computed for this stock yet, so there is no grade to show. The chapters above stand on the reported numbers.
The takeaway: MDCXW is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: the revenue breakdown.